US likely to authorise updated Covid booster shots for new Omicron variants

The US Food and Drug Administration is expected to approve new ovid-19 booster shots for newer Omicron strains this week, making them accessible to people in the country

Biological E, Covid vaccine
IANS New York
2 min read Last Updated : Aug 29 2022 | 1:17 PM IST

The US Food and Drug Administration (FDA) is expected to approve new covid-19 booster shots for newer Omicron strains this week, making them accessible to people in the country before any human testing is finished, the media reported.

The vaccines have been modified to target the most recent Omicron variant, but the US FDA won't have finished testing them on humans, the Daily Mail reported citing The Wall Street Journal.

The report mentioned that the FDA is instead relying on information from other sources, such as mice study and data from previous immunisation.

"Real world evidence from the current mRNA Covid-19 vaccines, which have been administered to millions of individuals, show us that the vaccines are safe," FDA Commissioner Robert Califf said in a tweet last week.

The official also wrote that the FDA will rely on the totality of the available evidence in making a decision.

This includes, clinical trial data from other bivalent mRNA Covid-19 boosters, RWE from current Covid-19 vaccines administered to millions of people, and non-clinical data for the bivalent BA.4/5 vaccines.

Clinical trial data, which will be used for the clearance of the vaccines, is similar to what the approach the FDA uses regarding flu shots, which are updated annually to keep up with mutating strains, the report said.

But some vaccine experts are not fans of the approach and believe it would be better to wait, rather than going with "mouse data", it added.

--IANS

vc/ksk/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineUSAUS Food and Drug Administration

First Published: Aug 29 2022 | 1:17 PM IST

Next Story